Thrombopoietin Receptor Agonist Market Segmentation:
Route of Administration Segment Analysis
In the route of administration segment, the oral sub-segment dominates the segment and is projected to hold the share value of 73.8% by 2035. The oral TPO-Ras is the patient's preferred route to support chronic management and minimize hospital dependency. As per the Agency for Healthcare Research and Quality data, the hospitalization time has been reduced via oral outpatient regimens and by enhancing cost efficiency in the healthcare sector. Further, CPI data has revealed that oral medications are prescribed mostly in the healthcare sector, which shows a steady rise in the pricing and reimbursement acceptance. The oral therapies have increased treatment adherence and improved the quality of care in patients.
Drug Class Segment Analysis
Under the drug class market, the non-peptidic TPO-RAs hold the largest segment share and are poised to have 68.5% of the share value in 2035. Non-peptide TPO-RAs, such as eltrombopag, avatrombopag, and lusutrombopag, are desired for oral bioavailability, a longer half-life, and excellent safety in prolonged administration, demonstrating efficacy in adult and pediatric chronic immune thrombocytopenic purpura and liver-disease-associated thrombocytopenia, as cited by FDA prescribing information and orphan drug designations. According to the NLM report published in March 2025, adults with chronic primary ITP discovered that the combination of avatrombopag with romiplostim and eltrombopag saved €6,083,231 over three years in drug and monitoring costs versus treatment without avatrombopag.
End user Segment Analysis
Hospitals lead the end-user segment and are expected to hold the share value of 61.4% by 2035. The segment is fueled by their primary role in starting treatment with immune thrombocytopenia (ITP), aplastic anemia, and chemotherapy-induced thrombocytopenia. Hospitals offer access to specialized hematology treatment, as New York Prebyterian report published in November 2024, nearly 3,000 children are affected due to the ITP in North America hospitals based on the diagnostic facilities, and parenteral administration equipment, mostly for peptidic TPO-RAs such as romiplostim that need healthcare provider oversight. Combination therapies and supportive care are also propelling this segment's growth through the trend towards such treatments and care in tertiary centers.
Our in-depth analysis of the Thrombopoietin Receptor Agonist market includes the following segments:
|
Segment |
Subsegments |
|
Drug Class |
|
|
Route of Administration |
|
|
Indication |
|
|
End user |
|
|
Distribution Channel |
|
